Prostate Cryoablation With Low-Dose Cyclophosphamide for Metastatic Prostate Cancer
Tests prostate freezing and cyclophosphamide added to hormone therapy in men with spread prostate cancer.
Plain-language title generated from the registry record
Registry title: Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer
Key facts
- Where
- Guangzhou, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06854250, who can take part
Where in China
- Sun Yat-sen University Cancer CenterGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sun Yat-sen University
- Trial code
- NCT06854250
- Record updated
- 28 August 2026
- Original description
The goal of this clinical trial is to explore whether androgen deprivation therapy combined with novel androgen receptor inhibitors, prostate cryoablation, and metronomic cyclophosphamide is superior to the current treatment regimen of androgen deprivation therapy plus novel androgen receptor inhibitors for patients with metastatic prostate cancer. It will also learn about the safety of prostate cryoablation, and metronomic cyclophosphamide for patients with metastatic prostate cancer. The main questions it aims to answer are:Read full original descriptionShow less
Androgen Deprivation Therapy Combined With Novel Androgen Receptor Inhibitors, Prostate Cryoablation, and Cyclophosphamide in the Treatment of Newly Diagnosed, Metastatic Prostate Cancer: A Single-Center, Single-Arm, Prospective Clinical Study
The goal of this clinical trial is to explore whether androgen deprivation therapy combined with novel androgen receptor inhibitors, prostate cryoablation, and metronomic cyclophosphamide is superior to the current treatment regimen of androgen deprivation therapy plus novel androgen receptor inhibitors for patients with metastatic prostate cancer. It will also learn about the safety of prostate cryoablation, and metronomic cyclophosphamide for patients with metastatic prostate cancer. The main questions it aims to answer are:
Does prostate cryoablation, and metronomic cyclophosphamide delay the progression of metastatic prostate cancer? Does prostate cryoablation, and metronomic cyclophosphamide reduce symptomatic local events of metastatic prostate cancer?
Researchers will explore if androgen deprivation therapy combined with novel androgen receptor inhibitors, prostate cryoablation, and metronomic cyclophosphamide works to treat metastatic prostate cancer.
Participants will:
Receive treatment of androgen deprivation therapy and novel androgen receptor inhibitors until progression.
Receive prostate cryoablation surgery and take cyclophosphamide. Visit the clinic every 1-3 months for checkups and tests. Keep a diary of their symptoms.
Inclusion: Males between 18 and 80 years old; Histopathological confirmation of prostatic acinar adenocarcinoma; Diagnosed with metastatic prostate cancer at initial diagnosis according to the AJCC 8th edition staging criteria; No progression at the time of initiating of prostate cryoablation; ECOG score of 0-1; Can tolerate general anesthesia and prostate cryoablation surgery; No significant abnormalities ; Able to understand this study and sign the informed consent form.
Exclusion: with prostate volumegreater than 55ml after 6 months of androgen deprivation therapy ; Serious illness not suitable to receive the treatment regimen; Other malignant tumors (within 5 years), except for non-melanoma skin cancer; Prostate cancer invading the rectum; Receipt of treatments other than treatment regimen of this study.